Rachel joined Bionest in 2010 as part of the New York office, and moved to Basel in 2015. Rachel works with teams from large pharma and biotech companies, on portfolio, asset development, and Go to Market strategies, with a particular focus in the oncology and CDx / biomarker spaces.
Prior to joining Bionest, Rachel completed a Ph.D. in Medical and Molecular Pharmacology at the University of California, Los Angeles. Her doctoral research was focused on tumor metabolism, with a focus on cancer immunotherapy and PET imaging biomarkers. Rachel also holds an MS in Neuropharmacology from the University of Oxford, and a B.S. in Molecular and Cell Biology from UCLA.
Listen to the interview (published November 2017). https://mendelspod.com/podcasts/immuno-oncology-2017-looking-back-lookin...
